Related Experiment Video
Updated: Jun 7, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
A New Frontier in Targeted Therapies: Harnessing PROTACs and Advanced Delivery Systems
1Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
Abstract:
In the rapidly evolving field of oncology, the need for innovative therapeutic strategies is more pressing than ever. Many cancers, especially those driven by gene mutations like KRAS, remain challenging to treat. Traditional approaches, which often rely on small-molecule inhibitors, face significant limitations, particularly in addressing "undruggable" targets or delivering large therapeutic molecules across cellular membranes. As highlighted by four essential patents, the recent advancements in Proteolysis Targeting Chimeras (PROTACs) and intracellular delivery systems offer novel and promising strategies to overcome these challenges.
Insights
Innovative cancer therapies are emerging to tackle difficult-to-treat mutations like KRAS. Proteolysis Targeting Chimeras (PROTACs) and advanced delivery systems offer new hope against challenging oncology targets.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Targeting KRAS mutations and other "undruggable" oncogenic drivers remains a significant challenge in cancer therapy.
- Conventional small-molecule inhibitors have limitations in efficacy and delivery for certain cancer targets.
- The development of novel therapeutic modalities is crucial for advancing cancer treatment strategies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Prodrugs
Prodrugs help overcome...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...

